Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The 3C study is investigating whether reducing exposure to calcineurin inhibitors (by using
more potent antibody induction treatment and/or an elective switch to sirolimus) can improve
the function and survival of kidney transplants.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Oxford
Collaborators:
National Health Service, United Kingdom Novartis Pfizer